De Clifford-Faugère Gwenaelle, Angarita-Fonseca Adriana, Nguefack Hermine Lore Nguena, Godbout-Parent Marimée, Audet Claudie, Lacasse Anaïs
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT).
Cannabis. 2024 Dec 12;7(3):120-133. doi: 10.26828/cannabis/2024/000263. eCollection 2024.
An increase in medical cannabis and prescribed cannabinoids use for chronic pain management has been observed in Canada in the past years. This study aimed to: 1) Describe clinicians' perceived risk associated with the use of medical cannabis and prescribed cannabinoids for the management of chronic pain; and 2) Identify sociodemographic and professional factors associated with perceived risk of adverse effects.
A web-based cross-sectional study was conducted in Quebec, Canada in 2022. A convenience sample of 207 clinicians was recruited (physicians/pharmacists/nurse practitioners). They were asked to rate the risk of adverse effects associated with medical cannabis (e.g., smoke, or oil) and prescribed cannabinoids (e.g., nabilone) on a scale of 0 to 10 (0: no risk, 10: very high risk), respectively. Multiple linear regression was performed to identify factors associated with perceived risk.
Average perceived risk associated with medical cannabis and prescribed cannabinoids were 5.93 ± 2.08 (median:6/10) and 5.76 ± 1.81 (median:6/10). Factors associated with higher medical cannabis perceived risk were working in primary care (β = 1.38, = .0034) or in another care setting (β = 1.21, = .0368) as compared to a hospital setting. As for prescribed cannabinoids, being a pharmacist (β = 1.14, = .0452), working in a primary care setting (β = 0.83, = .0408) and reporting more continuing education about chronic pain (β = 0.02, = .0416) were associated with higher perceived risk. No sex differences were found in terms of perceived risk.
Considering the clinician's experience provide insights on cannabis risk as these professionals are at the forefront of patient care when they encounter adverse effects.
在过去几年中，加拿大使用医用大麻和处方类大麻素治疗慢性疼痛的情况有所增加。本研究旨在：1）描述临床医生对使用医用大麻和处方类大麻素治疗慢性疼痛所感知到的风险；2）确定与感知到的不良反应风险相关的社会人口学和专业因素。
2022年在加拿大魁北克进行了一项基于网络的横断面研究。招募了207名临床医生（医生/药剂师/执业护士）作为便利样本。要求他们分别对与医用大麻（如烟雾或油剂）和处方类大麻素（如纳布啡）相关的不良反应风险在0至10的量表上进行评分（0：无风险，10：非常高的风险）。进行多元线性回归以确定与感知风险相关的因素。
与医用大麻和处方类大麻素相关的平均感知风险分别为5.93±2.08（中位数：6/10）和5.76±1.81（中位数：6/10）。与较高的医用大麻感知风险相关的因素是与医院环境相比，在初级保健机构工作（β=1.38，P=.0034）或在其他护理环境中工作（β=1.21，P=.0368）。至于处方类大麻素，作为药剂师（β=1.14，P=.0452）、在初级保健机构工作（β=0.83，P=.0408）以及报告更多关于慢性疼痛的继续教育（β=0.02，P=.0416）与较高的感知风险相关。在感知风险方面未发现性别差异。
考虑到临床医生的经验有助于了解大麻风险，因为这些专业人员在遇到不良反应时处于患者护理的前沿。
